82 0

AstraZeneca's vaccine was tested in multiple countries, including Brazil, the U.S. and the U.K. NELSON ALMEIDA/AFP via Getty Images. Pharmaceutical giant AstraZeneca and its partner Oxford University released preliminary results from its phase 3 Covid-19 vaccine trials on Monday, which found that the company’s vaccine, which uses a genetically modified cold virus, is up to 90% effective. This makes AstraZeneca the third to announce preliminary data from its phase 3 trials, after Moderna and Pfizer released results from their phase 3 trials earlier this month. Both Moderna and Pfizer, whose vaccines use an mRNA platform, found their vaccines to be about 95% effective. The AstraZeneca/Oxfo... Vollständiger Text

23 November